HC Reform Update by Mark Sanna: On July 1, the House of Representatives passed a bill that would crack down on a devious tactic used by some pharmaceutical companies. The tactic, known as “pay for delay,” involves business deals in which the makers of patented brand-name drugs pay generic competitors to delay the introduction of cheaper alternatives. Now it will be up to the Senate to approve the bill.